Brief: Entera Bio Announces Excellent Topline Phase 2 BMD Data For EB613

Entera Bio

23/06/2021 14:08

June 23 (Reuters) - Entera Bio Ltd  5DT.F :
    * ENTERA BIO ANNOUNCES EXCELLENT TOPLINE PHASE 2 BMD DATA
FOR
EB613, THE STUDY MET ITS PRIMARY AND KEY SECONDARY ENDPOINTS
    * ENTERA BIO - SUBJECTS RECEIVING 2.5 MG DOSE OF EB613
SHOWED
SIGNIFICANT DOSE-RELATED INCREASES IN BMD AT LUMBAR SPINE, TOTAL
HIP, FEMORAL NECK AT 6 MONTHS
    * ENTERA BIO LTD - SUBJECTS RECEIVING 2.5 MG DOSE OF EB613
FOR 6
MONTHS HAD A SIGNIFICANT PLACEBO ADJUSTED INCREASE OF 3.78% IN
LUMBAR SPINE BMD
    * ENTERA BIO LTD - EB613 EXHIBITED AN EXCELLENT SAFETY
PROFILE,
WITH NO DRUG RELATED SERIOUS ADVERSE EVENTS
    * ENTERA BIO LTD - AN END OF PHASE 2 MEETING WITH FDA TO
REVIEW
EB613 DEVELOPMENT PROGRAM IS ANTICIPATED IN COMING MONTHS

Source text for Eikon:  ID:nGNX6HMyWK 
Further company coverage:  5DT.F 

 ((Reuters.Briefs@thomsonreuters.com;))